Smoking Cessation Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | CTC Bio, Eolas, GlaxoSmithKline, NFL Biosciences, Novo Nordisk, Pfizer

Smoking Cessation Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | CTC Bio, Eolas, GlaxoSmithKline, NFL Biosciences, Novo Nordisk, Pfizer
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Smoking Cessation therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Smoking Cessation Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Smoking Cessation Market. 

The Smoking Cessation Pipeline report embraces in-depth commercial, regulatory, and Smoking Cessation clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the emerging Smoking Cessation drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Smoking Cessation Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Smoking Cessation treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Smoking Cessation therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Smoking Cessation companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Smoking Cessation drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Smoking Cessation therapeutic market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Smoking Cessation Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Smoking Cessation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Smoking Cessation Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

Smoking Cessation Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Smoking Cessation. Currently, Embera NeuroTherapeutics, Inc is leading the therapeutics market with its Smoking Cessation drug candidates in the most advanced stage of clinical development.

Smoking Cessation Companies Actively Working in the Therapeutic Market Include:

  • Achieve Life Sciences

  • AstraZeneca

  • Axsome Therapeutics

  • Boryung Pharmaceutical

  • Camino Pharma

  • Chronic Airway Therapeutics

  • CTC Bio

  • Embera NeuroTherapeutics, Inc.

  • Eolas Therapeutics

  • GlaxoSmithKline

  • Novo Nordisk

  • Pfizer

  • Smoke Free Therapeutics (NFL Biosciences SAS)

And Many Others

Emerging and Marketed Smoking Cessation Drugs Covered in the Report Include:

  • EMB-001: Embera NeuroTherapeutics, Inc.

  • SBP 9330: Camino Pharma

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Smoking Cessation Companies Working in the Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Smoking Cessation Treatment Patterns

4. Smoking Cessation – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Smoking Cessation Late Stage Products (Phase-III)

7. Smoking Cessation Mid-Stage Products (Phase-II)

8. Smoking Cessation Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Smoking Cessation Discontinued Products

13. Smoking Cessation Product Profiles

14. Major Smoking Cessation Companies in the Market

15. Key Products in the Smoking Cessation Therapeutics Segment

16. Dormant and Discontinued Products

17. Smoking Cessation Unmet Needs

18. Smoking Cessation Future Perspectives

19. Smoking Cessation Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports By DelveInsight

Pleural Effusion Market

Pleural Effusion Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Pleural Effusion market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Pleural Effusion market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States